Engineered immune cells target Hard-to-Treat childhood cancers

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. The approach uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein called GD2. These cells are combined with a chickenpox vaccine to help them survive longer in the body. The main goals are to find a safe dose and to see if the treatment can shrink tumors.